205 related articles for article (PubMed ID: 34384312)
1. Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Woyach J; Tedeschi A; Munir T; Siddiqi T; Hillmen P; Byrd JC; Ghia P; Mulligan SP; Dai S; Amaya-Chanaga CI; Dean JP; O'Brien SM; Barr PM
Leuk Lymphoma; 2021 Dec; 62(13):3278-3282. PubMed ID: 34384312
[No Abstract] [Full Text] [Related]
2. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
İskender G; İskender D; Ertek M
Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
[No Abstract] [Full Text] [Related]
3. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
Molica S; Baumann T; Giannarelli D
Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
[No Abstract] [Full Text] [Related]
4. Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.
Molica S; Allsup DJ; Polliack A
Leuk Lymphoma; 2022 Aug; 63(8):1771-1773. PubMed ID: 35703117
[No Abstract] [Full Text] [Related]
5. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
[No Abstract] [Full Text] [Related]
6. Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia.
Mehraban Far P; Rullo J; Farmer J; Urton T
Ocul Immunol Inflamm; 2022 May; 30(4):1005-1008. PubMed ID: 33539715
[TBL] [Abstract][Full Text] [Related]
7. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
[No Abstract] [Full Text] [Related]
8. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
Molica S; Giannarelli D; Baumann T; Montserrat E
Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067
[No Abstract] [Full Text] [Related]
9. Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases.
Coppola PE; Broccoli A; Argnani L; Casadei B; Stefoni V; Bertuzzi C; Sabattini E; Zinzani PL
Leuk Lymphoma; 2021 Dec; 62(14):3540-3543. PubMed ID: 34348068
[No Abstract] [Full Text] [Related]
10. Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
Barnea Slonim L; Ma S; Behdad A; Chen Q
Br J Haematol; 2020 Oct; 191(1):e22-e25. PubMed ID: 32677079
[No Abstract] [Full Text] [Related]
11. Zanubrutinib more effective and better tolerated than ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma.
Nierengarten MB
Cancer; 2023 May; 129(10):1466. PubMed ID: 37088994
[No Abstract] [Full Text] [Related]
12. Ibrutinib-Induced Skin Rash.
Kirar S; Gogia A; Gupta R; Mallick S
Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
[No Abstract] [Full Text] [Related]
13. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
14. Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study.
Ysebaert L; Quinquenel A; Bijou F; Ferrant E; Michallet AS;
Eur J Cancer; 2020 Aug; 135():170-172. PubMed ID: 32585590
[No Abstract] [Full Text] [Related]
15. Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
Martín-Moro F; García-Cosío M; Marquet-Palomanes J; López-Gutiérrez M; Pian-Arias H; López-Jiménez FJ
Ann Hematol; 2022 Jan; 101(1):213-215. PubMed ID: 33423076
[No Abstract] [Full Text] [Related]
16. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
17. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Langerbeins P; Zhang C; Robrecht S; Cramer P; Fürstenau M; Al-Sawaf O; von Tresckow J; Fink AM; Kreuzer KA; Vehling-Kaiser U; Tausch E; Müller L; Eckart MJ; Schlag R; Freier W; Gaska T; Balser C; Reiser M; Stauch M; Wendtner CM; Fischer K; Stilgenbauer S; Eichhorst B; Hallek M
Blood; 2022 Jan; 139(2):177-187. PubMed ID: 34758069
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
[TBL] [Abstract][Full Text] [Related]
19. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
20. Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
Molica S; Giannarelli D; Visentin A; Reda G; Sportoletti P; Frustaci AM; Chiarenza A; Ciolli S; Vitale C; Laurenti L; De Paoli L; Murru R; Gentile M; Moia R; Rigolin GM; Levato L; Giordano A; Del Poeta G; Stelitano C; Deodato M; Ielo C; Noto A; Guarente V; Coscia M; Tedeschi A; Gaidano G; Cuneo A; Foa' R; Trentin L; Mauro FR
Am J Hematol; 2022 May; 97(5):E176-E180. PubMed ID: 35170793
[No Abstract] [Full Text] [Related]
[Next] [New Search]
